Bristol/Medarex Ipilimumab Toxicity Signals Efficacy, Investigator Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The immune response side effects of ipilimumab serve as an efficacy signal for the melanoma therapy, according to one of the lead investigators studying the Bristol-Myers Squibb/Medarex immunotherapeutic